For personal use only

Xenitra™

ASX Announcement

Scaling brands in Asia with *authentic products* and *loyal* customers

ASX: XEN

Xenitra.com

24 August 2026

XENITRA RAISES A$1.5M TO ACCELERATE HIGH-MARGIN SALES GROWTH

Xenitra Limited (ASX:XEN) (Xenitra or the Company) is pleased to announce that it has received firm commitments from sophisticated and professional investors to raise A$1.5 million before costs through a placement of 500,000,000 new fully paid ordinary shares at A$0.003 per share (Placement).

Investors will receive one free-attaching option for every two Placement Shares, exercisable at A$0.004 on or before 2 April 2028 (Placement Options). The Placement Options will be issued subject to shareholder approval.

HIGHLIGHTS

- **A$1.5 million placement:** firm commitments received from sophisticated and professional investors.
- **Offer price of A$0.003:** a 6.25% discount to the 15-trading-day VWAP.
- **Rapidly accelerate higher-margin sales:** proceeds will expand inventory procurement, supplier capacity, order fulfilment, ecommerce activation and brand and distributor onboarding across OTC Medicines, FSMP and OPAL.
- **OTC commercial momentum:** A$450,000 in initial Fukang orders fulfilled in July 2026 (preliminary and unaudited), supported by the operational Hong Kong pharmaceutical platform and the three-year Kangsheng agreement carrying a minimum A$12 million procurement commitment.
- **New FSMP growth channel:** the recently announced Joy Charm framework agreement targets A$5 million in Food for Special Medical Purposes procurement over three years, with individual purchase orders governing product, pricing, delivery and payment terms.
- **OPAL sales traction:** more than A$1.5 million in tokenised product sales and over 500 distribution partners onboarded in less than one quarter following launch.
- **A stronger operating platform:** the latest reported quarter delivered A$800,000 in positive operating cash flow, a 16% gross-margin improvement and approximately A$1 million in annualised operating savings.

PLACEMENT TERMS

Term	Details
Gross proceeds	A$1.5 million before costs
Placement Shares	500,000,000 new fully paid ordinary shares
Offer Price	A$0.003 per Placement Share
Placement Options	250,000,000 free-attaching options on a 1-for-2 basis, exercisable at A$0.004 on or before 2 April 2028, subject to shareholder approval
Offer Price discount	6.25% discount to the 15-trading-day VWAP
Lead Manager	Novus Capital Limited
Lead Manager terms	6% cash fee (including management fee), 15,000,000 Broker Shares and 30,000,000 Broker Options, with the securities subject to shareholder approval
Indicative allotment	Monday, 7 September 2026

Xenitra™

ASX Announcement

Scaling brands in Asia with *authentic products* and *loyal* customers

ASX: XEN

Xenitra.com

24 August 2026

GROWTH CAPITAL FOR COMMERCIAL EXECUTION

Xenitra has moved rapidly from strategic reset to commercial execution across its Nutritionals and FMCG, OTC Medicines and OPAL businesses. The Placement will provide working capital for the business and to expand sales capacity: increasing the Company's ability to procure inventory, satisfy supplier terms, fulfil customer and distributor demand and activate new brands and products through its established China sales channels.

This focus is consistent with Xenitra's transition away from a predominantly low-margin distribution model toward a diversified cross-border healthcare and digital-commerce platform with materially higher-margin sales channels.

OTC Medicines - a scalable pharmaceutical channel now in market

The acquisition of Hong Kong Fukang Trading Co. established an operational OTC Medicines platform incorporating a Hong Kong pharmaceutical wholesale licence, experienced local team, warehousing and logistics capability and an active JD.com OTC storefront. Initial Fukang activity generated and fulfilled approximately A$450,000 in orders during July 2026 (preliminary and unaudited).

The minimum A$12 million three-year procurement agreement with Kangsheng Pharmaceuticals Hong Kong Group provides commercial validation and a pathway to scale. Additional working capital will enable Xenitra to deepen inventory, widen its online product range and support a faster conversion of customer demand and procurement schedules into sales.

OPAL - early sales validation and expanding distribution

OPAL has generated more than A$1.5 million in tokenised product sales and onboarded over 500 distribution partners in less than one quarter. Placement proceeds will support the onboarding of additional international FMCG brands and distributors, expand product availability and strengthen the ecommerce and tokenisation infrastructure required to lift transaction volume. OPAL's tokenised sales model has a substantially higher margin profile than Xenitra's historical nutritionals distribution business.

FSMP - extending the healthcare platform into medical foods

The Joy Charm framework agreement announced on 18 August 2026 targets A$5 million in FSMP procurement over three years and extends Xenitra's healthcare offering into regulated medical foods. The target is not a guaranteed minimum and sales will arise through individual purchase orders. The Placement gives Xenitra greater capacity to source products, support supplier and logistics requirements and fulfil purchase orders as the relationship is activated.

USE OF FUNDS - CONVERTING DEMAND INTO HIGHER-MARGIN SALES

- **OTC and FSMP inventory and fulfilment:** fund supplier payments, product procurement, inventory depth, logistics and purchase-order execution under the Kangsheng and Joy Charm relationships.
- **Ecommerce range expansion:** accelerate new product listings, online activation and sales through Fukang's established Hong Kong and mainland China channels, including the JD.com storefront.
- **OPAL scale-up:** onboard additional brands and distribution partners and support the sales, ecommerce and tokenisation infrastructure required to increase tokenised product volumes.
- **Growth working capital and infrastructure:** support the Company's ongoing corporate costs through the coming financial year, together with the costs of the Placement.

CHAIRMAN'S COMMENTS

Dr Anthony Noble, Chairman of Xenitra, said:

"Xenitra has spent the past year rebuilding the business around cash discipline and higher-margin growth. The result is a leaner platform that is already producing positive operating cash flow, while OTC Medicines, FSMP and OPAL are creating new commercial pathways at pace.

"This raising is deliberately focused on execution. It gives us working capital to support the ongoing operations of the business, including to purchase and move inventory, fulfil demand, widen our online product range and accelerate the onboarding of brands and distributors into OPAL. Our objective is straightforward: convert the agreements, channels and customer demand we have established into rapidly growing, higher-margin sales.

"We appreciate the support of participating investors and look forward to delivering Xenitra's next phase of commercial growth."

For personal use only

24 August 2026

PLACEMENT STRUCTURE AND LEAD MANAGER

The 500,000,000 Placement Shares are expected to be issued under the Company's existing placement capacity pursuant to ASX Listing Rules 7.1 and 7.1A.

Novus Capital Limited acted as Lead Manager to the Placement and will receive a 6% cash fee, inclusive of its management fee. Novus will also receive 15,000,000 fully paid ordinary shares and 30,000,000 options on the same terms as the Placement Options. The Placement Options and the Lead Manager securities will be subject to shareholder approval.

-Ends-

This announcement has been approved for release by the Board of Xenitra Limited.

INVESTOR RELATIONS CONTACT

Harry Spillane | Investor Relations
harry@blackwateradvisors.com.au
+61 447 757 550

ABOUT XENITRA LIMITED

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals, over the counter (OTC) medicines and personal care products distributed through a channel-optimised sales ecosystem incorporating blockchain-enabled tokenised distribution channels spanning Business-to-Business (B2B) trading, retail distribution and ecommerce platforms in China. Xenitra is one of the first Australian companies to commercially deploy Real World Asset (RWA) tokenisation integrated directly into mainstream FMCG sales channels in China. The Company's established ecommerce, livestream commerce and distributor infrastructure across China and Australia provides a scalable platform to onboard additional international and domestic brands into the OPAL ecosystem.

FORWARD LOOKING STATEMENTS

This announcement may contain forward-looking statements, including statements regarding plans, strategies and objectives of management; anticipated sales, revenues, margins, procurement, products, distribution, platform expansion, operating costs and commercial outcomes. Forward-looking statements can be identified using terminology such as 'intend', 'aim', 'project', 'anticipate', 'estimate', 'plan', 'believe', 'expect', 'may', 'should', 'will', 'continue' or similar words. These statements are not guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control and may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by applicable law or regulation, the Company does not undertake any obligation to publicly update or review any forward-looking statement. Past performance cannot be relied on as a guide to future performance.

For personal use only